Identification
- Generic Name
- Elsamitrucin
- DrugBank Accession Number
- DB05129
- Background
The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Elsamitrucin (DB05129)
- Weight
- Average: 653.6299
Monoisotopic: 653.210840211 - Chemical Formula
- C33H35NO13
- Synonyms
- Elsamitrucin
- External IDs
- BBM-2478A
- BMY-28090
Pharmacology
- Indication
Investigated for use/treatment in lymphoma (non-hodgkin's).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Elsamitrucin induces single strand breaks in DNA and inhibits topoisomerase I and II, enzymes that play an important role in DNA replication.
Target Actions Organism UDNA Not Available Humans UDNA topoisomerase 1 Not Available Humans UDNA topoisomerase 2-alpha Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
36–60 h
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Elsamitrucin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Elsamitrucin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Elsamitrucin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Elsamitrucin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Elsamitrucin is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthopyranone glycosides. These are compounds containing a carbohydrate moiety glycosidically linked to a naphthopyranone moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Naphthopyrans
- Sub Class
- Naphthopyranones
- Direct Parent
- Naphthopyranone glycosides
- Alternative Parents
- Aminoglycosides / Phenolic glycosides / O-glycosyl compounds / Naphthols and derivatives / Coumarins and derivatives / Isocoumarins and derivatives / Disaccharides / 1-benzopyrans / 2-benzopyrans / Pyranones and derivatives show 13 more
- Substituents
- 1-benzopyran / 1-naphthol / 2-benzopyran / Acetal / Alcohol / Amine / Amino saccharide / Aminoglycoside core / Aromatic heteropolycyclic compound / Benzenoid show 29 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- ZTV0FOB6NU
- CAS number
- 97068-30-9
- InChI Key
- MGQRRMONVLMKJL-KWJIQSIXSA-N
- InChI
- InChI=1S/C33H35NO13/c1-11-9-10-16-19-17(11)29(38)46-25-18-14(24(36)21(20(19)25)30(39)44-16)7-6-8-15(18)45-32-28(33(4,40)27(37)13(3)43-32)47-31-22(34)26(41-5)23(35)12(2)42-31/h6-10,12-13,22-23,26-28,31-32,35-37,40H,34H2,1-5H3/t12-,13-,22-,23+,26-,27+,28+,31-,32+,33+/m1/s1
- IUPAC Name
- 3-{[(2S,3R,4S,5S,6R)-3-{[(2R,3R,4R,5S,6R)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.0^{2,7}.0^{9,19}.0^{16,20}]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione
- SMILES
- CO[C@@H]1[C@@H](N)[C@@H](O[C@H]2[C@H](OC3=CC=CC4=C3C3=C5C(C(=O)OC6=C5C(=C(C)C=C6)C(=O)O3)=C4O)O[C@H](C)[C@H](O)[C@]2(C)O)O[C@H](C)[C@@H]1O
References
- General References
- Klein I, Welink J, van der Vijgh WJ: Determination of Elsamitrucin (BMY-28090) in plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1993 Dec 22;622(2):249-53. [Article]
- External Links
- PubChem Compound
- 5362259
- PubChem Substance
- 175426950
- ChemSpider
- 4514988
- ChEMBL
- CHEMBL2106409
- ZINC
- ZINC000004215770
- Wikipedia
- Elsamitrucin
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Completed Treatment Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) / Mantle Cell Lymphoma (MCL) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.379 mg/mL ALOGPS logP 1.95 ALOGPS logP 2.35 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 9.1 Chemaxon pKa (Strongest Basic) 7.98 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 12 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 205.69 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 160.65 m3·mol-1 Chemaxon Polarizability 64.52 Å3 Chemaxon Number of Rings 7 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7734 Blood Brain Barrier - 0.9941 Caco-2 permeable - 0.6837 P-glycoprotein substrate Substrate 0.5965 P-glycoprotein inhibitor I Non-inhibitor 0.799 P-glycoprotein inhibitor II Non-inhibitor 0.8061 Renal organic cation transporter Non-inhibitor 0.9595 CYP450 2C9 substrate Non-substrate 0.8065 CYP450 2D6 substrate Non-substrate 0.8871 CYP450 3A4 substrate Non-substrate 0.5112 CYP450 1A2 substrate Non-inhibitor 0.8134 CYP450 2C9 inhibitor Non-inhibitor 0.9139 CYP450 2D6 inhibitor Non-inhibitor 0.926 CYP450 2C19 inhibitor Non-inhibitor 0.8572 CYP450 3A4 inhibitor Non-inhibitor 0.7817 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8862 Ames test AMES toxic 0.5534 Carcinogenicity Non-carcinogens 0.9308 Biodegradation Not ready biodegradable 0.9923 Rat acute toxicity 2.2177 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9875 hERG inhibition (predictor II) Non-inhibitor 0.9097
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 244.8119 predictedDeepCCS 1.0 (2019) [M+H]+ 246.8847 predictedDeepCCS 1.0 (2019) [M+Na]+ 253.05629 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Unknown
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Poly(a) rna binding
- Specific Function
- Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a singl...
- Gene Name
- TOP1
- Uniprot ID
- P11387
- Uniprot Name
- DNA topoisomerase 1
- Molecular Weight
- 90725.19 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ubiquitin binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
- Gene Name
- TOP2A
- Uniprot ID
- P11388
- Uniprot Name
- DNA topoisomerase 2-alpha
- Molecular Weight
- 174383.88 Da
Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51